2022 World Conference on Lung Cancer (ePosters)-EP08.02-158. Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC

EP08.02-158. Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC

Back to course

Pdf Summary

The ALTER-L018 trial evaluated the combination of anlotinib and docetaxel as a second-line treatment for patients with EGFR-negative advanced non-small cell lung cancer (NSCLC). The study showed that the combination therapy significantly improved progression-free survival (PFS) compared to docetaxel alone. The median PFS was 4.36 months in the combination therapy group, compared to 1.64 months in the docetaxel-only group. The combination therapy also resulted in a higher objective response rate (ORR) and disease control rate (DCR). The safety profile of the combination therapy was manageable, with fatigue being the most common adverse event. Overall, the combination of anlotinib and docetaxel is considered an effective second-line treatment option for EGFR-negative NSCLC patients who have progressed after first-line platinum-based chemotherapy.

Asset Subtitle

Lin Wu

Meta Tag

Speaker Lin Wu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ALTER-L018 trial

anlotinib

docetaxel

second-line treatment

EGFR-negative

advanced non-small cell lung cancer

NSCLC

progression-free survival

objective response rate

disease control rate